Medivir (STO:MVIRB) will be conducting an analyst and investor conference call/webcast today 3 November, at 14.30 CET. Niklas Prager CEO, Ola Burmark CFO and Richard Bethell CSO will be presenting and will be available for questions relating to the recent agreement to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals Corporation.
To join the conference call, please dial:
Sweden +46 (0)8 566 426 96
Europe +44 20 300 898 17
USA +1 855 831 5946
The webcast can be accessed on the website: www.medivir.com.
About Medivir Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005577/en/Business Wire
Last updated on: 03/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.